Archive for September 2018
Epidiolex (Cannabidiol) is a Schedule V Controlled Substance
Yesterday, the Drug Enforcement Administration announced that Epidiolex, which contains cannabidiol (CBD), a chemical constituent of the cannabis or marijuana plant is a Schedule V Controlled Substance, which is the least restrictive schedule of the Controlled Substance Act. In June 2018, the Food and Drug Administration announced it approved Epidiolex (cannabidiol), for the treatment of…
Read MoreFDA and Responsible Opioid Prescribing for Pain Management in Animals
The Food and Drug Administration (FDA) continues to address the opioid epidemic on all fronts with regards to prescribing opioids in humans. But, last month, the FDA introduced a new resource containing information and recommendations specifically for veterinarians who stock and administer opioids. The FDA recommends veterinarians take the following steps if they stock and…
Read MoreOpioid Crisis Response Act Passed By Senate
Yesterday, the US Senate passed an opioid bill – The Opioid Crisis Response Act – that addresses illicit fentanyl trafficking via the mail system, drug diversion in opioid manufacturing quotas and aims to improve access to addiction treatment via telemedicine. The ‘STOP Act’, drafted by Ohio Senator Rob Portman, addresses the illegal importation of illicit fentanyl…
Read MoreColorado Limits Access to Products with Dextromethorphan
On August 8, 2018, House Bill 18-1307, which limits access to products with dextromethorphan, went into effect. Dextromethorphan is an active ingredient in many over-the-counter (OTC) cough medicines as it is widely used as a cough suppressant. When taken according to labeling instructions, dextromethorphan can be safe and effective. However, when dextromethorphan is taken in…
Read More